Postmenopausal evaluation and risk reduction with lasofoxifene (PEARL) trial: 5-year gynecological outcomes

Menopause

Volumn 18, Issue 1, 2011, Pages 17-22

  Goldstein, Steven R ^a   Neven, Patrick ^b   Cummings, Steven ^c   Colgan, Terence ^d   Runowicz, Carolyn D ^e   Krpan, Dalibor ^f   Proulx, James ^g   Johnson, Margot ^g   Thompson, David ^g   Thompson, John ^g   Sriram, Usha ^h  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MOUNT SINAI HOSPITAL   (Canada)

^e UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^f Policlinic K center   (Croatia)

^g PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^h Associates in Clinical Endocrinology   (India)

Author keywords

Cancer; Endometrial; Gynecologic.; Hyperplasia; Lasofoxifene; Postmenopausal

Indexed keywords

CALCIUM; LASOFOXIFENE; PLACEBO; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; ENDOMETRIAL DISEASE; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM HYPERTROPHY; ENDOMETRIUM POLYP; FEMALE; FEMUR NECK; FRAGILITY FRACTURE; HUMAN; HUMAN TISSUE; HYPERTROPHY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVARY CANCER; PELVIC ORGAN PROLAPSE; PELVIS; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SPINE; TREATMENT OUTCOME; URINE INCONTINENCE; UTERUS MYOMA; VAGINA BLEEDING; VAGINA CANDIDIASIS; VAGINA DISCHARGE; VAGINA PAIN; VAGINAL BURNING SENSATION;

AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIAN CYSTS; OVARIAN NEOPLASMS; POLYPS; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; PYRROLIDINES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TETRAHYDRONAPHTHALENES; URINARY INCONTINENCE; UTERINE DISEASES; UTERUS;

EID: 78651407344     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181e84bb4     Document Type: Article

References (16)

1. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.
2. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-2197.
3. Cummings SR, Ensrud KE, Delmas PD, et al. Lasofoxifene for postmenopausal women with osteoporosis. N Engl J Med 2010;362:686-696.
4. Reese PR, Pleil AM, Okano GJ, Kelleher CJ. Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder. Qual Life Res 2003;12:427-442.
5. Baden WF, Walker TA, Lindsey JH. The vaginal profile. Tex Med 1968;64:56-58.
6. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry. Estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptomsVrecommendations for clinical evaluation. US FDA Web site. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/ InformationbyDrugClass/UCM135338.pdf. Accessed December 18, 2009.
7. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical investigation of medicinal products for the treatment of hormone replacement therapy. European Medicines Agency Web site. Available at: http://www.emea.europa.eu/ pdfs/human/ewp/002197en.pdf. Accessed December 18, 2009.
8. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996;275:370-375.
9. Martino S, Disch D, Dowsett SA, Keech CA, Mershon JL. Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin 2005;21:1441-1452.
10. Goldstein RB, Bree RL, Benson CB, et al. Evaluation of the woman with postmenopausal bleeding: Society of Radiologists in Ultrasound- Sponsored Consensus Conference statement. J Ultrasound Med 2001;20: 1025-1036.
11. ACOG Committee Opinion No. 426: the role of transvaginal ultrasonography in the evaluation of postmenopausal bleeding. Obstet Gynecol 2009;113:462-464.
12. McClung MR, Siris E, Cummings S, et al. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause 2006;13:377-386.
13. Ke HZ, Paralkar VM, Grasser WA, et al. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models. Endocrinology 1998;139: 2068-2076.
14. Ke HZ, Foley GL, Simmons HA, Shen V, Thompson DD. Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology 2004;145:1996-2005.
15. Powles TJ, Bourne T, Athanasiou S, et al. The effects of norethisterone on endometrial abnormalities identified by transvaginal ultrasound screening of healthy post-menopausal women on tamoxifen or placebo. Br J Cancer 1998;78:272-275.
16. Goldstein SR, Neven P, Zhou L, Taylor YL, Ciaccia AV, Plouffe L. Raloxifene effect on frequency of surgery for pelvic floor relaxation. Obstet Gynecol 2001;98:91-96.